Analysis · Global
THC and CBD for Dementia Agitation: What the LiBBY Trial Actually Found
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Research
Clinical trials, cannabinoid science, and the evidence shaping policy.
Analysis · UK
Can CBD Oil Trigger a Drug Test? What the Evidence Actually Says
A new systematic review finds that pure CBD is not the main problem. Undeclared THC, inconsistent products and blunt testing policies are where the real risk sits.
Analysis · Global
Key Cannabinoid Research Studies to Watch in 2026
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Analysis · Global
CBD for Anxiety: Promise Is Still Running Ahead of Proof
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
Analysis · Global
THC and Chronic Pain: The Evidence Is Growing, but the Caveats Matter
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
Analysis · Global
Beyond THC and CBD: The Emerging Science of Terpenes
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.
Analysis · USA
FDA Unveils Long-Awaited CBD Regulatory Framework, Sparking Industry Debate
FDA releases March 2026 draft guidance on hemp-derived CBD, proposing a 20 mg daily cap and strict labelling rules for a $4B+ market.